Related Experiment Video

Updated: Oct 3, 2025

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

10.9K

All roads lead to targeted diffuse large B-cell lymphoma approaches

Peng-Peng Xu1, Yu-Jia Huo1, Wei-Li Zhao2

  • 1Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.

Cancer Cell
|February 15, 2022
PubMed

Insights

Novel targeted therapies show promise for treating diffuse large B-cell lymphoma (DLBCL). Further research aims to make DLBCL curable through precision medicine approaches.

Area of Science:

  • Oncology
  • Hematology
  • Pharmacology

Background:

  • Diffuse large B-cell lymphoma (DLBCL) remains a significant challenge in hematologic malignancies.
  • Advances in targeted therapies offer new hope for improving patient outcomes.

Purpose of the Study:

  • To summarize recent advancements in targeted therapies for DLBCL.
  • To emphasize the potential of precision medicine in achieving DLBCL curability.

Main Methods:

  • Review of recent clinical trial data and published reports.
  • Analysis of novel targeted therapy mechanisms and their clinical impact.

Main Results:

  • Successful application of novel targeted therapies has improved clinical outcomes in DLBCL patients.
  • Demonstrated efficacy of specific targeted agents in recent studies.

Conclusions:

  • Targeted therapies represent a significant breakthrough in DLBCL treatment.
  • Continued research into mechanism-based therapies is crucial for realizing the goal of DLBCL cure in the precision medicine era.

More Related Videos

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.2K
A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells12:16

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

Published on: October 16, 2018

15.0K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
711